激素替代治疗冻融胚胎移植后根据黄体期支持方案比较生殖结局:随机对照试验的系统评价与网络Meta分析
该系统评价与网络Meta分析纳入10项随机对照试验共4216例患者,比较9种激素替代治疗冻融胚胎移植的黄体期支持方案。口服地屈孕酮联合促性腺激素释放激素激动剂在持续妊娠与活产联合结局中排名最高(SUCRA=97.3%),但证据确定性极低至低;仅分析活产时阴道栓剂孕酮排名最高(SUCRA=89.7%)。
要点
- 共纳入10项随机对照试验、4216例患者,比较9种黄体期支持方案。
- 口服地屈孕酮联合GnRHa在持续妊娠与活产联合结局中显著优于其他方案,SUCRA=97.3%。
- 仅分析活产时阴道栓剂孕酮排名最高(SUCRA=89.7%),仅与肌注孕酮及肌注联合阴道孕酮相比有显著差异。
核心结论
- 极低至低确定性证据表明,口服地屈孕酮联合GnRHa和单用阴道栓剂孕酮可能是提高激素替代治疗冻融胚胎移植妇女活产率和持续妊娠率最有前景的黄体期支持方案。
- 由于证据确定性低且部分结局分析存在不一致性、缺乏明确排名第一的治疗,强调需要进一步开展随机对照试验。
研究设计与样本
- 系统评价与网络Meta分析,检索MEDLINE、Scopus、LILACS、EMBASE、Scielo.br、PROSPERO、CINAHL、PsycINFO、AMED、ClinicalTrials.gov、ICTRP、Cochrane Library及会议论文集,无日期、地域或语言限制。
- 纳入所有将不孕妇女分配至至少两种不同激素类黄体期支持方案的随机对照试验,组间基线特征相似。
- 共纳入10项随机对照试验,4216例患者,分配至9种不同黄体期支持方案。
- 采用随机效应网络Meta分析进行直接和间接配对比较,以累积排名曲线下面积(SUCRA)对方案排序;使用Cochrane偏倚风险工具版本1评估偏倚风险,采用CINeMA标准评价证据确定性。
主要发现
- 对于持续妊娠与活产联合结局,口服地屈孕酮联合GnRHa与所有其他黄体期支持方案相比显著更有效(证据确定性极低至低),SUCRA分析将其排名为首选治疗(SUCRA=97.3%)。
- 仅分析活产时,阴道栓剂孕酮更可能为首选治疗(SUCRA=89.7%),但配对分析中仅与肌注孕酮相比(OR 0.53,95%CI 0.33-0.84;低确定性证据)及与肌注孕酮联合阴道栓剂孕酮相比(OR 0.47,95%CI 0.32-0.69;低确定性证据)有显著差异。
- 对于临床妊娠率,各治疗间无显著差异(证据确定性极低至低),阴道栓剂孕酮联合人绒毛膜促性腺激素排名最高(SUCRA=33.7%)。
- 对于流产率,肌注孕酮联合阴道栓剂孕酮与任一单药治疗相比显著更有效(低确定性证据),且最可能排名第一(SUCRA=51.4%)。
关键数值与推荐
- 主要结局为活产率和持续妊娠与活产联合率;次要结局为临床妊娠率和流产率。
- 持续妊娠与活产联合结局:口服地屈孕酮联合GnRHa的SUCRA=97.3%。
- 活产结局:阴道栓剂孕酮的SUCRA=89.7%;与肌注孕酮相比OR 0.53(95%CI 0.33-0.84),与肌注孕酮联合阴道栓剂孕酮相比OR 0.47(95%CI 0.32-0.69)。
- 临床妊娠率:阴道栓剂孕酮联合人绒毛膜促性腺激素的SUCRA=33.7%。
- 流产率:肌注孕酮联合阴道栓剂孕酮的SUCRA=51.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 证据确定性为极低至低。
- 部分结局的分析存在不一致性,缺乏明确排名第一的治疗。
- 强调需要进一步开展随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare reproductive outcome between luteal-phase support (LPS) protocols for frozen embryo transfer (FET) cycles with hormone replacement therapy (HRT). METHODS: A search was conducted in MEDLINE, Scopus, LILACS, EMBASE, Scielo.br, PROSPERO, CINAHL, PsycINFO, AMED, ClinicalTrials.gov, ICTRP, the Cochrane Library and conference proceedings, with no restrictions on date, geography or language. We included all randomized controlled trials (RCTs) that allocated infertile women to at least two different hormone-based LPS protocols for HRT-FET, with similar baseline characteristics between groups. The Preferred Reporting Items for Systematic reviews and Meta-Analyses extension statement for network meta-analyses (PRISMA-NMA) was followed. A random-effects network meta-analysis was performed for direct and indirect pairwise comparisons to rank available LPS protocols by the surface under the cumulative ranking curve area (SUCRA). Risk of bias was assessed using the Cochrane risk-of-bias tool version 1. Certainty of evidence was evaluated using the Confidence in Network Meta-Analysis (CINeMA) criteria. The primary outcomes were the live birth rate and the combined rate of ongoing pregnancy and live birth; the secondary outcomes were the clinical pregnancy rate and the pregnancy loss rate. RESULTS: Ten RCTs assigned a total of 4216 patients to nine different LPS approaches. Regarding the combined outcome of ongoing pregnancy and live birth, oral dydrogesterone (DYD) combined with gonadotropin-releasing hormone agonist (GnRHa) was significantly more efficacious compared with all other LPS protocols (very low to low certainty of evidence), with SUCRA analysis ranking it as the treatment of choice (SUCRA = 97.3%). When the analysis was restricted to live birth only, vaginal suppository progesterone showed a higher likelihood of being the treatment of choice (SUCRA = 89.7%), but only exhibited a significant difference on pairwise analysis when compared with intramuscular progesterone (odds ratio (OR), 0.53 (95% CI, 0.33-0.84); low certainty of evidence) and intramuscular progesterone + vaginal suppository progesterone (OR, 0.47 (95% CI, 0.32-0.69); low certainty of evidence). For the clinical pregnancy rate, no significant differences between treatments were found (very low to low certainty of evidence), with vaginal suppository progesterone + human chorionic gonadotropin being the highest-ranked treatment (SUCRA = 33.7%). For pregnancy loss rate, intramuscular progesterone + vaginal suppository progesterone was significantly more efficacious compared with either treatment alone (low certainty of evidence), and had the highest chance of being the top-ranked treatment (SUCRA = 51.4%). CONCLUSIONS: There is very-low-to-low-certainty evidence that oral DYD + GnRHa and vaginal suppository progesterone alone could be the most promising LPS approaches to increase the rates of live birth and ongoing pregnancy in women undergoing HRT-FET. However, the low certainty of evidence and the lack of a clear first-ranked treatment, due to inconsistencies in the analysis for some outcomes, stress the need for further RCTs on this subject. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Etrusco A, Ata B, Agrifoglio V, et al. Reproductive outcome after frozen embryo transfer with hormone replacement therapy according to luteal-phase support protocol: systematic review and network meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2025. PMID: 40746270. doi:10.1002/uog.29302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。